MUC1 and liver cancer: Previously, we reported that PNA-modified liposomes showed enhanced drug delivery efficiency toward MUC1-positive liver cancer cells, which suggested the feasibility of using PNA-modified liposomes targeting MUC1 as a means to enhance its antitumor effects (Li, Diao, et al., 2020).